Experts from the US Food and Drug Administration’s official official agency of best vaccines suggest that they oppose the widespread use of the two COVID-19 vaccines, a newly released document shows.
Dr Vinai Prasad, director of the agency’s Center for Biological Assessment and Research, said in two notes he opposed the reviewer’s conclusions on the safety of the vaccine and the ongoing threat of the virus that causes COVID-19, especially for young and healthy people.
Prasad’s decision is in line with the broader Trump administration efforts under the leadership of US Health and Human Services Secretary Robert F. Kennedy Jr. to limit the availability of coronavirus vaccinations. Kennedy said in May that shots would no longer be recommended for healthy children and pregnant people. The FDA said it would approve the new Covid-19 vaccine before that month, but would only approve elderly and high-risk groups.
In a memo that week, Prasad rejected recommendations from around 30 FDA scientists for people over the age of 12. He cited limited data and “lower risk” of severe COVID-19 infections and safety concerns.
He cited similar safety concerns in a May 30 document entitled “Override Memo” on the widespread use of Modern’s latest version of mRNA vaccine Mnexspike. The company had applied for approval for the updated version for people over the age of 12.
Prasad writes that despite the overall data submitted by Moderna, he was unable to conclude that the manufacturer had improved the safety of the shots or raised concerns about the risk of myocarditis or heart inflammation in teens and young people.
Earlier that week, the FDA had advised Moderna and another manufacturer of mRNA Covid-19 vaccine Pfizer to update the label to include warnings about this rare condition.
“Novavax is focused on making Covid-19 vaccinations available to those who choose to receive vaccinations at the highest risk,” the company said in a statement Wednesday. “We believe it is important for consumers to choose a vaccine.
Moderna declined to comment on the story.
“The idea that Dr. Prasad ‘dismissed’ FDA scientists is a distortion of fact,” HHS spokesman Andrew Nixon said in a statement to CNN on Wednesday. “He evaluated the whole evidence and made judgments rooted in gold standard science. It’s not political. It’s what principled leadership looks like.”
Dr. Daniel Griffin, an infectious disease expert at Columbia University, said the memo reflects a broader talk point among health officials.
“They seem to be obsessed with myocarditis and they made the decision simply because they have a fixed ideology that they continue to look for confirmation bias,” he said. “And I think the data there is really clear. Early on, I saw 20 to 65 (cases) per million doses when I was giving the first (vaccine) 3-4 weeks apart. In fact, we didn’t really see much in reality. It’s 10 times more expensive than if you were protected by a vaccine.
The memo also marks a break from typical agency responsibilities, Griffin said.
“The role of the FDA is to make decisions whether or not to obtain a license. However, as long as we limit access, we are to provide guidance on who should be vaccinated. The FDA is supposed to have the power to limit access to safe and effective products.”
“In the past, override memos for the centre director have been rare and only made after very careful consideration, usually after consultation with other centre directors,” Dr. Peter Marks, director of Cber before Prasad, told a text message Wednesday.
Dr. Peter Lurie, former FDA Associate Commissioner, now president and executive director of the Center for Public Interest Science, said overrides like Prasad tend to be false in the aspect of being less restrictive and tend to make the product available when reviewers become more cautious. He has never seen reviewers limit the use of products they deemed safe and effective.
“It’s very difficult to escape the conclusion that these Covid vaccines’ resentment plays a key role in this very rare override,” he said. “Yes, I think there is still concern that they were making policy decisions that should have been reserved for the CDC.”
Prasad’s memo was first reported by the New York Times.
Prasad took on the role as CBER director on May 8 after saying Marks was kicked out of his role due to Kennedy’s vaccine strategy. More recently, FDA commissioner Dr. Marty McCurry has also promoted Prasad to become the agency’s Chief Medical and Scientific Officer.
Prasad is a hematologist oncologist and an outspoken critic of his claims to be thinking of a medical group. Former University of California In clinical trials, the San Francisco professor also questioned the dependence of developers on drug approval processes and secondary outcomes or surrogate endpoints, as well as the dependence of drug approval processes and developers.
Prasad called “former FDA commissioners, both democratic and Republican administrations, who do not need sufficient randomized clinical trial data for approval decisions, “under both Democrat and Republican administrations.”
The biotech stock fell a few hours after it was announced as CBER director. Some industry analysts called Prasad the “anti-establishment” pick and led the division overseeing vaccines and biological products.
He appears to nod his concerns with McCurry at City Hall on May 20, suggesting a flexible approach to speeding up drug approval.
“We must always accept surrogate endpoints for people with illnesses, extremely rare conditions and few treatment options,” he told FDA staff at the Maryland campus. “We have an obligation to promote the FDA to patients who desperately want those products, and we also have an obligation to check our backend and make sure we are actually achieving what we thought.”
Prasad also showed an approach to the Covid-19 vaccine at its city hall.
“The risk of severe illness and hospitalization is declining among Americans. The effectiveness of repeat doses… The effectiveness of these vaccines further reduce severe illness and symptomatic illness is uncertain, and there are important safety considerations that have not been fully known for their long-term effects,” he said. “We will continue to monitor them closely.”
